Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Lancet Psychiatry Review Flags Escitalopram, Duloxetine, Agomelatine in Long-Term Study

Lancet Psychiatry Review Flags Escitalopram, Duloxetine, Agomelatine in Long-Term Study

November 22, 2026 Health Desk Health

A systematic review of 115 randomized controlled trials, encompassing more than 30,000 patients, identifies specific antidepressants that may offer superior long-term symptom management for major depressive disorder.

The analysis, published on November 10, 2026, in The Lancet Psychiatry, compares the efficacy and acceptability of 21 different medications used to prevent relapse in adults.

Key Clinical Takeaways:

  • Escitalopram, duloxetine, and agomelatine demonstrated a higher likelihood of sustained response compared to fluoxetine.
  • Patients prescribed escitalopram or duloxetine showed higher rates of treatment adherence, measured by lower trial drop-out rates.
  • The majority of analyzed trials were assessed as having a high risk of bias, suggesting that these findings require cautious clinical interpretation.

Study Finds Escitalopram, Duloxetine, Agomelatine Outperform Fluoxetine

The research, led by Paul C.F. van Haaren and colleagues at Radboud University Medical Centre, utilized a network meta-analysis to synthesize data from trials lasting longer than 12 weeks.

While fluoxetine served as the reference point for the study, the investigators found that escitalopram, duloxetine, and agomelatine were associated with a greater likelihood of maintaining a therapeutic response. For those utilizing escitalopram and duloxetine, the data also indicated a higher probability of remaining on the prescribed medication compared to those taking fluoxetine, according to ScienceDaily.

The study highlights a clinical gap regarding long-term maintenance therapy. In the 2024–2025 period, 3.8 million Australians were dispensed antidepressants, yet clinical guidelines typically suggest treatment durations of six to 12 months.

Evidence suggests many patients remain on these medications for significantly longer, with some studies indicating an average duration of four years. Because depressive episodes can recur, selecting a medication that balances symptom suppression with tolerability remains a critical component of psychiatric care.

Best Antidepressants for Long-Term Maintenance? (115-Trial Lancet Study) — The MD Briefing | Global Medical Updates

Limitations in Long-Term Clinical Evidence

Despite the large sample size, the researchers said that more than half of the included trials were classified as having a high risk of bias. This classification stems from limitations in the original study designs rather than inherent pharmacological deficiencies.

The duration of the trials poses a challenge to long-term conclusions; most direct comparisons followed participants for only six months. Only six of the 115 trials monitored patients beyond this window, leaving a deficit of data regarding the multi-year efficacy of these pharmaceutical interventions.

The study was conducted by an international team including researchers from the University of Oxford and Kyoto University. While the findings provide a framework for comparing drug performance, they represent aggregate outcomes that do not account for individual patient variability. Factors such as preexisting health conditions, potential side effects, and personal response histories are primary determinants in selecting an appropriate pharmacological path.

Escitalopram Leads the Way: Major Study Reveals Which Antidepressants Work Best at Preventing Rel… — TheReelyNews

Clinical Considerations for Treatment Maintenance

Determining the appropriate antidepressant involves weighing the trade-off between symptom control and quality of life. For many, the decision to continue or discontinue medication is complicated by the risk of withdrawal symptoms. Clinical consensus emphasizes that any modification to a treatment regimen must occur gradually and under the direct supervision of a medical professional. Abrupt cessation can lead to significant physiological discomfort and an increased risk of relapse.

The study shows that while some medications appear more favorable in a controlled setting, these results are not definitive for every individual. Patients who are currently stable on a medication that is not among those flagged as most effective in this analysis should not necessarily consider a switch.

The primary goal remains the sustained management of depression through a combination of pharmacological support, psychological therapy, and lifestyle adjustments. For individuals experiencing difficulty with their current treatment protocol, engaging with a board-certified psychiatrist or a mental health professional is essential to evaluate alternative therapeutic strategies.

The researchers acknowledged that their synthesis of trial drop-out rates serves as a proxy for acceptability, which may not fully capture the nuance of a patient’s daily experience.

Future research is required to better understand the long-term impact of these treatments beyond the six-month mark. The current evidence base remains incomplete, particularly regarding the comparative performance of medications over the multi-year periods that are increasingly common in real-world clinical practice.

Paul C.F. van Haaren, the first author of this study, is a researcher based at the Radboud University Medical Centre. His work on this systematic review represents the first large-scale effort to conduct a comparative analysis of different antidepressants specifically across both short-term and long-term use.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Keep reading

  • Expert Warns Bótox for Bruxism Is Not a Universal Cure, Urges Diagnosis First
  • WhatsApp Tests Native Cloud Backup for Android With 2 GB Free Encrypted Storage

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service